Ameritas Investment Partners’s Crescent Biopharma CBIO Stock Holding History

Ameritas Investment Partners’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30	Closed	-$9K	–	3131
2021 Q1	$9K	Hold	30	–	–	﹤0.01%	2892
2020 Q4	$11K	Hold	30	–	–	﹤0.01%	2747
2020 Q3	$9K	Hold	30	–	–	﹤0.01%	2764
2020 Q2	$11K	Hold	30	–	–	﹤0.01%	2671
2020 Q1	$7K	Hold	30	–	–	﹤0.01%	2680
2019 Q4	$16K	Hold	30	–	–	﹤0.01%	2513
2019 Q3	$13K	Hold	30	–	–	﹤0.01%	2615
2019 Q2	$36K	Hold	30	–	–	﹤0.01%	2102
2019 Q1	$37K	Hold	30	–	–	﹤0.01%	2050
2018 Q4	$28K	Hold	30	–	–	﹤0.01%	2139
2018 Q3	$43K	Hold	30	–	–	﹤0.01%	2073
2018 Q2	$48K	Buy	+30	New	+$51.6K	﹤0.01%	2006
2017 Q2	–	Sell	-8	Closed	-$4K	–	3014
2017 Q1	$4K	Buy	+8	New	+$4.91K	﹤0.01%	2870

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's CBIO Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 30 shares — an estimated $9K sold.

Ameritas Investment Partners first reported a position in CBIO in Q1 2017 and held it in 13 quarters. The position peaked at $48K in Q2 2018. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

Ameritas Investment Partners reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Partners sold 30 Crescent Biopharma shares in Q2 2021, an estimated $9K.
Ameritas Investment Partners first reported a position in Crescent Biopharma in Q1 2017 and held it in 13 quarters.
Ameritas Investment Partners's Crescent Biopharma position peaked at $48K in Q2 2018.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.